The risk of acquiring HIV from an HIV positive source patient ranges from 0.2% to 0.5%. On the other hand, the risk of contracting Hepatitis C from a Hepatitis C positive source patient is estimated to be between 3% and 10%.

When it comes to post-exposure prophylaxis for HIV, it is crucial to administer it within 72 hours after a needle-stick injury. The effectiveness of this prophylaxis decreases with time, so it should be given as soon as possible after the incident. For detailed guidelines on post-exposure prophylaxis, please refer to the DOH guidelines.

Unfortunately, there is currently no post-exposure prophylaxis available for Hepatitis C. However, there is a class of antiviral medications called nucleotide polymerase inhibitors that have revolutionized the treatment of Hepatitis C. These medications, such as sofosbuvir and daclatasvir, have shown remarkable efficacy in curing more than 90% of people with Hepatitis C. Moreover, they are easier to tolerate and have shorter treatment courses, making them a significant advancement in Hepatitis C treatment.

The CIWA scale, also known as the Clinical Institute Withdrawal Assessment for Alcohol scale, is a scale consisting of ten items that is utilized in the evaluation and management of alcohol withdrawal. It is currently recommended by both NICE and the Royal College of Emergency Medicine for assessing patients experiencing acute alcohol withdrawal. The maximum score on the CIWA scale is 67, with scores indicating the severity of withdrawal symptoms. A score of less than 5 suggests mild withdrawal, while a score between 6 and 20 indicates moderate withdrawal. Any score above 20 is considered severe withdrawal. The ten items evaluated on the scale encompass common symptoms and signs of alcohol withdrawal, such as nausea/vomiting, tremors, sweating, anxiety, agitation, sensory disturbances, and cognitive impairments.

In addition to the CIWA scale, there are other screening tools available for assessing various conditions. The CAGE questionnaire is commonly used to screen for alcohol-related issues. The STEPI is utilized as a screening tool for early symptoms of the schizophrenia prodrome. The EPDS is an evidence-based questionnaire that can be employed to screen for postnatal depression. Lastly, the SCOFF questionnaire is a screening tool used to identify the possible presence of eating disorders.

For further information on the assessment and management of acute alcohol withdrawal, the NICE pathway is a valuable resource. The RCEM syllabus also provides relevant information on this topic. Additionally, the MHC1 module on alcohol and substance misuse offers further reading material for those interested in this subject.

Urticaria is a condition characterized by a raised, itchy rash on the skin and mucous membranes. It can be localized or widespread and affects about 15% of people at some point in their lives. There are two forms of urticaria: acute and chronic, with the acute form being more common.

In about 50% of cases of acute urticaria, a specific trigger can be identified. Common triggers include allergies (such as foods, bites, stings, and drugs), skin contact with irritants (like chemicals, nettles, and latex), physical stimuli (such as firm rubbing, pressure, and extremes of temperature), and viral infections.

The main skin lesion seen in urticaria is called a wheal or wheel. Wheals typically have three characteristics: a central swelling that can be red or white in color, surrounded by a red area (known as the flare), and they are usually very itchy, sometimes accompanied by a burning sensation. Wheals are temporary and usually disappear within 1 to 24 hours, returning the skin to its normal appearance.

Wheals can vary in size, ranging from a few millimeters to lesions as large as 10 cm in diameter. They can appear as single lesions or multiple ones, and sometimes they merge together to form large patches. In some cases, urticaria can also cause swelling of the soft tissues in the eyelids, lips, and tongue, known as angioedema.

The internal jugular vein is a significant vein located close to the surface of the body. It is often chosen for the insertion of central venous catheters due to its accessibility. To locate the vein, a needle is inserted into the middle of a triangular area formed by the lower heads of the sternocleidomastoid muscle and the clavicle. It is important to palpate the carotid artery to ensure that the needle is inserted to the side of the artery.

In the treatment of diabetic ketoacidosis (DKA), it is important to continue the infusion of insulin until certain criteria are met. These criteria include ketone levels being less than 0.3 mmol/L and the pH of the blood being above 7.3 or the bicarbonate levels being above 18 mmol/L. Additionally, the patient should feel comfortable enough to eat at this point. It is crucial not to stop the intravenous insulin infusion until at least 30 minutes after administering subcutaneous short-acting insulin.

Further Reading:

Diabetic ketoacidosis (DKA) is a serious complication of diabetes that occurs due to a lack of insulin in the body. It is most commonly seen in individuals with type 1 diabetes but can also occur in type 2 diabetes. DKA is characterized by hyperglycemia, acidosis, and ketonaemia.

The pathophysiology of DKA involves insulin deficiency, which leads to increased glucose production and decreased glucose uptake by cells. This results in hyperglycemia and osmotic diuresis, leading to dehydration. Insulin deficiency also leads to increased lipolysis and the production of ketone bodies, which are acidic. The body attempts to buffer the pH change through metabolic and respiratory compensation, resulting in metabolic acidosis.

DKA can be precipitated by factors such as infection, physiological stress, non-compliance with insulin therapy, acute medical conditions, and certain medications. The clinical features of DKA include polydipsia, polyuria, signs of dehydration, ketotic breath smell, tachypnea, confusion, headache, nausea, vomiting, lethargy, and abdominal pain.

The diagnosis of DKA is based on the presence of ketonaemia or ketonuria, blood glucose levels above 11 mmol/L or known diabetes mellitus, and a blood pH below 7.3 or bicarbonate levels below 15 mmol/L. Initial investigations include blood gas analysis, urine dipstick for glucose and ketones, blood glucose measurement, and electrolyte levels.

Management of DKA involves fluid replacement, electrolyte correction, insulin therapy, and treatment of any underlying cause. Fluid replacement is typically done with isotonic saline, and potassium may need to be added depending on the patient’s levels. Insulin therapy is initiated with an intravenous infusion, and the rate is adjusted based on blood glucose levels. Monitoring of blood glucose, ketones, bicarbonate, and electrolytes is essential, and the insulin infusion is discontinued once ketones are below 0.3 mmol/L, pH is above 7.3, and bicarbonate is above 18 mmol/L.

Complications of DKA and its treatment include gastric stasis, thromboembolism, electrolyte disturbances, cerebral edema, hypoglycemia, acute respiratory distress syndrome, and acute kidney injury. Prompt medical intervention is crucial in managing DKA to prevent potentially fatal outcomes.

Gynaecomastia, a condition characterized by the enlargement of breast tissue in males, can be caused by certain drugs. Some medications that have been associated with gynaecomastia include Cimetidine, Omeprazole, Spironolactone, Digoxin, Furosemide, Finasteride, and certain antipsychotics. Interestingly, Ranitidine, another medication commonly used for gastric issues, does not tend to cause gynaecomastia. In fact, studies have shown that gynaecomastia caused by Cimetidine can be resolved when it is substituted with Ranitidine.

The symptoms and signs of strokes can vary depending on which blood vessel is affected. Here is a summary of the main symptoms based on the territory affected:

Anterior cerebral artery: This can cause weakness on the opposite side of the body, with the leg and shoulder being more affected than the arm, hand, and face. There may also be minimal loss of sensation on the opposite side of the body. Other symptoms can include difficulty speaking (dysarthria), language problems (aphasia), apraxia (difficulty with limb movements), urinary incontinence, and changes in behavior and personality.

Middle cerebral artery: This can lead to weakness on the opposite side of the body, with the face and arm being more affected than the leg. There may also be a loss of sensation on the opposite side of the body. Depending on the dominant hemisphere of the brain, there may be difficulties with expressive or receptive language (dysphasia). In the non-dominant hemisphere, there may be neglect of the opposite side of the body.

Posterior cerebral artery: This can cause a loss of vision on the opposite side of both eyes (homonymous hemianopia). There may also be defects in a specific quadrant of the visual field. In some cases, there may be a syndrome affecting the thalamus on the opposite side of the body.

It’s important to note that these are just general summaries and individual cases may vary. If you suspect a stroke, it’s crucial to seek immediate medical attention.

When treating adults with bradycardia, a maximum of 6 doses of atropine 500 mcg can be administered. Each dose is given intravenously every 3-5 minutes. The total dose should not exceed 3mg.

Further Reading:

Causes of Bradycardia:
– Physiological: Athletes, sleeping
– Cardiac conduction dysfunction: Atrioventricular block, sinus node disease
– Vasovagal & autonomic mediated: Vasovagal episodes, carotid sinus hypersensitivity
– Hypothermia
– Metabolic & electrolyte disturbances: Hypothyroidism, hyperkalaemia, hypermagnesemia
– Drugs: Beta-blockers, calcium channel blockers, digoxin, amiodarone
– Head injury: Cushing’s response
– Infections: Endocarditis
– Other: Sarcoidosis, amyloidosis

Presenting symptoms of Bradycardia:
– Presyncope (dizziness, lightheadedness)
– Syncope
– Breathlessness
– Weakness
– Chest pain
– Nausea

Management of Bradycardia:
– Assess and monitor for adverse features (shock, syncope, myocardial ischaemia, heart failure)
– Treat reversible causes of bradycardia
– Pharmacological treatment: Atropine is first-line, adrenaline and isoprenaline are second-line
– Transcutaneous pacing if atropine is ineffective
– Other drugs that may be used: Aminophylline, dopamine, glucagon, glycopyrrolate

Bradycardia Algorithm:
– Follow the algorithm for management of bradycardia, which includes assessing and monitoring for adverse features, treating reversible causes, and using appropriate medications or pacing as needed.
https://acls-algorithms.com/wp-content/uploads/2020/12/Website-Bradycardia-Algorithm-Diagram.pdf

The correct answer is 10-15%. This means that out of all phaeochromocytoma cases, approximately 10-15% occur outside of the adrenal glands.

Further Reading:

Phaeochromocytoma is a rare neuroendocrine tumor that secretes catecholamines. It typically arises from chromaffin tissue in the adrenal medulla, but can also occur in extra-adrenal chromaffin tissue. The majority of cases are spontaneous and occur in individuals aged 40-50 years. However, up to 30% of cases are hereditary and associated with genetic mutations. About 10% of phaeochromocytomas are metastatic, with extra-adrenal tumors more likely to be metastatic.

The clinical features of phaeochromocytoma are a result of excessive catecholamine production. Symptoms are typically paroxysmal and include hypertension, headaches, palpitations, sweating, anxiety, tremor, abdominal and flank pain, and nausea. Catecholamines have various metabolic effects, including glycogenolysis, mobilization of free fatty acids, increased serum lactate, increased metabolic rate, increased myocardial force and rate of contraction, and decreased systemic vascular resistance.

Diagnosis of phaeochromocytoma involves measuring plasma and urine levels of metanephrines, catecholamines, and urine vanillylmandelic acid. Imaging studies such as abdominal CT or MRI are used to determine the location of the tumor. If these fail to find the site, a scan with metaiodobenzylguanidine (MIBG) labeled with radioactive iodine is performed. The highest sensitivity and specificity for diagnosis is achieved with plasma metanephrine assay.

The definitive treatment for phaeochromocytoma is surgery. However, before surgery, the patient must be stabilized with medical management. This typically involves alpha-blockade with medications such as phenoxybenzamine or phentolamine, followed by beta-blockade with medications like propranolol. Alpha blockade is started before beta blockade to allow for expansion of blood volume and to prevent a hypertensive crisis.

During pregnancy, genital warts have the potential to grow larger in size and increase in number. This is because pregnancy causes a state of immunosuppression, which means that the patient’s immune system is unable to effectively suppress the latent HPV virus. Additionally, there are other factors that can contribute to the growth of genital warts. These include areas of moist skin, non-hair bearing skin, poor hygiene, and the presence of vaginal discharge.